Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Argos Aims To Automate Cell-Based Cancer Therapy

This article was originally published in Start Up

Executive Summary

Eventually, someone is going to have clinical and commercial success with a personalized cancer therapy. Learning from the mistakes of Dendreon and others, Argos Therapeutics expects to be first, and automation is its key.

You may also be interested in...



Argos Nears Phase III Results For Precision Cancer Immunotherapy

With pivotal data expected in 2017 in metastatic kidney cancer, Argos hopes its drug will bridge the hot points of immuno-oncology and personalized medicine with a drug that extract’s RNA from a patient’s tumor and primes the dendritic cells to teach the immune system how to kill the cancer.

Unum Therapeutics Inc.

Unum Therapeutics Inc. is developing a new way of treating cancer that combines components of two different immune-system cells, natural killer cells and T cells. The start-up's therapeutic approach calls for modifying patients' own T cells with a hybrid molecule, called an antibody-coupled T-cell receptor , then co-administering them with antibodies designed to recognize specific proteins on the surface of tumors.

Cancer Immunotherapy: Mixing, Matching, And Making Nice

Cancer immunotherapy's potential payoff is big enough that acknowledged competitors are settling disputes, potential competitors are forging alliances, and start-ups like their chances of success. Profiles of Annias Immunotherapeutics, Costanoan Immunotherapies, and Unum Therapeutics.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC092554

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel